Navigation Links
Thesan Pharmaceuticals udpeger Dr. Bhaskar Chaudhuri til bestyrelsen i august 2014
Date:8/25/2014

SAN DIEGO, 25. august 2014 /PRNewswire/ -- Thesan Pharmaceuticals meddelte i dag, at firmaet udpeger Bhaskar Chaudhuri Ph.D. til bestyrelsen. Dr. Chaudhuri har mere end 25 års erfaring i ledelse inden for lægemidler, medicinsk forskning og udvikling og markedsføring i USA, EU og nye markeder. Han har ledet udviklingen og FDA-godkendelsen af flere NDA'er og ANDA'er. Senest var Dr. Chaudhuri adm. direktør for Valeant Phamaceutikals, før han blev arbejdende partner i Frazier Healthcare. Før Dr. Chaudhuri kom til Valeant var han adm. direktør for Dow Pharmaceuticals i perioden op til dette firmas opkøb af Valeant. Før Dow arbejdede Dr. Chaudhuri hos Bertek Pharmaceuticals (et datterselskab af Mylan Laboratories) som viceadm. direktør for videnskab og som direktør for dermatologiafdelingen hos Mylan Laboratories. Dr. Chaudhuri har et doktorat i fysisk farmakopé. Har er også medlem af bestyrelsen for flere lægemiddelselskaber.

"Vi er glade for at få Bhaskar i bestyrelsen på nuværende tidspunkt", sagde Gordon Foulkes, Thesan's adm. direktør. "Hans fantastiske CV inden for udvikling af dermatologimidler, hans markedsføringsekspertise og lederrolle i salget af flere dermatologiselskaber vil blive en fantastisk hjælp hos Thesan, når vi starter på at bygge et lederteam op for fremtiden".

"Jeg er helt klart beæret over at blive et medlem af Thesan-teamet", tilføjede Dr. Chaudhuri. Den aktuelle portefølje af banebrydende produkter, der ledes af et team af verdensklasse, giver Thesan grundlag for at være et ekstraordinært dermatologiselskab. Jeg ser frem til at bidrage til Thesans vækst og blive en del af en førende dermatologiorganisation".

Samtidig og i forbindelse med den nylige Serie B-finansiering vil Dr. Peter Moldt fra Novo Ventures blive det nye Novo-bestyrelsesmedlem, som repræsentant for dette firmas investering i Thesan. Dr. Moldt har masser af erfaring inden for bioteknologi og har været enten adm. direktør, produktionsdirektør eller udviklingschef i en række succesfulde selskaber, herunder Curalogic A/S, som han grundlagde og senere bragte på børsen i 2006. Dr. Moldt kom til Novo Ventures i 2009.

Om Thesan Pharmaceuticals, Inc.

Thesan er et bioteknologisk selskab, der fokuserer på udviklingen og markedsføringen af ny medicin til behandling af dermatologiske lidelser.
Flere oplysninger kan fås på: www.thesanpharma.com

Kontakt:
J. Gordon Foulkes, Ph.D.
Administrerende direktør
Thesan Pharmaceuticals, Inc.
Info@ThesanPharma.com


'/>"/>
SOURCE Thesan Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing
2. Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody
3. RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2014
4. Global Medical Imaging Reagents (Nanoparticles, Fluorescent Proteins, Fluorescent Dyes and Probes, Radiopharmaceuticals and Quantum Dots) Market - Forecast to 2019
5. Oramed Pharmaceuticals Reports Last Patient Out in Phase IIa Trial for ORMD-0801 in Type 1 Diabetes
6. OncoGenex Pharmaceuticals Announces Appointment of John A. Bencich as Vice President and Chief Financial Officer
7. RXi Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell
8. RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars
9. Galmed Pharmaceuticals Reports First Half 2014 Financial Results
10. SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services
11. Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 22, 2017 , ... ... RegMedNet has produced a Spotlight series on “Cell Therapy ... and perspectives by leading experts on the unique regulatory challenges of stem cell ...
(Date:6/22/2017)... ... June 22, 2017 , ... The first human cell line HeLa, ... the first data on cross-contamination of human cell lines with HeLa cells were published. ... in cell culture labs and is associated with dramatic consequences for research. , ...
(Date:6/22/2017)... ... June 22, 2017 , ... Charm Sciences, Inc. is pleased to announce that ... to be appropriate as a screening test at dairies and farms for raw commingled ... and the Charm EZ Lite system. These systems are a combination incubator and reader ...
(Date:6/20/2017)... ... June 20, 2017 , ... Biologist Dawn Maslar MS has ... her latest book, Men Chase, Women Choose: The Neuroscience of Meeting, Dating, Losing Your ... physiological effect on men. ”The logical next step, in my estimation, was to scientifically ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
Breaking Biology News(10 mins):